主要研究成果
[1] Fugui Zhou, Yiqing Zhou, Zhiyong Guo, Xianjun Yu, Zhangshuang Deng*. Review of 10,11-Dehydrocurvularin: Synthesis, Structural Diversity, Bioactivities and Mechanisms. Mini-Rev. Med. Chem., 2021, DOI: 10.2174/1389557521666210428132256. [2] Qun Zhao#, Yun Bi# (co-first author), Jing Zhong, Xiang Li, Jian Guo, Ying-xiang Liu, Long-rui Pan, Yan Tan, Zhang-shuang Deng*, Xian-jun Yu*. 10,11-Dehydrocurvularin exerts antitumor effect against human breast cancer by suppressing STAT3 activation. Acta Pharmacol. Sin. 2021, 2021, 42(5), 791-800. [3] Nai-Kei Wong#, Sunyun Zhong#(co-first author), Weichao Li, Fugui Zhou, Zhang-Shuang Deng*, Yiqing Zhou*. Selective profiling of steviol-catalyzing UDP-glycosyltransferases with a metabolically synthesized probe. Chem. Commun. 2020, 56(82), 12387-12390. [4] Yue Xu#, Zhangshuang Deng# (co-first author), Yue Shi, Xin Chen, Jingyuan Xu, Suyun Zhong, Youli Xiao, Nai-Kei Wong, Yiqing Zhou*. Molecular Imaging and In Situ Quantitative Profiling of Fatty Acid Synthase with a Chemical Probe. Anal. Chem. 2020, 92(6), 4419-4426. [5] Zhangshuang Deng, Nai-Kei Wong, Zhiyong Guo, Kun Zou, Youli Xiao, Yiqing Zhou*. Dehydrocurvularin is a potent antineoplastic agent irreversibly blocking ATP-citrate lyase: evidence from chemoproteomics. Chem. Commun. 2019, 55(29), 4194-4197. |